Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer

INTRODUCTION: Many patients with human epidermal growth factor receptor-2-positive metastatic breast cancer (HER2+ mBC) require subsequent lines of therapy (LOTs) after being treated with pertuzumab and trastuzumab-based regimens in the first line (1L). Although the efficacy of the second-line (2L)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Sandhya, Xie, Jipan, Ionescu-Ittu, Raluca, Nie, Xiaoyu, Kwong, Winghan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673796/
https://www.ncbi.nlm.nih.gov/pubmed/37715853
http://dx.doi.org/10.1007/s40487-023-00241-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673796/
https://www.ncbi.nlm.nih.gov/pubmed/37715853
http://dx.doi.org/10.1007/s40487-023-00241-8

Ejemplares similares